Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study

NCT03224923 is registered in ClinicalTrials.gov with Ottawa Heart Institute Research Corporation as lead sponsor.

NCT NCT03224923
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03224923 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Reassessment of Long-Term Dual Anti-Platelet Therapy Using InDividualized Strategies - Using a Novel Combined Demographic and Pharmacogenomic Strategy: The RAPID EXTEND Pilot Study
Lead sponsor
Ottawa Heart Institute Research Corporation
Phase
Phase 4
Overall status
Terminated
Start date
August 18, 2017
Completion date
September 30, 2018
Enrollment
5 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

antiplatelet therapy, percutaneous coronary intervention, stable coronary syndrome, ticagrelor